Hypothesis

Chronic low‑dose emodin supplementation increases pain tolerance and reduces epigenetic age acceleration in older adults by suppressing EGFR‑driven microglial activation and downstream inflammatory signaling.

Rationale

• Pain sensitivity correlates with epigenetic age acceleration (Hannum clock) and altered immune profiles in discordant twins1.
• Age‑related pain processing changes involve neuroinflammation, particularly microglial activation2.
• Emodin inhibits EGFR/MAPK signaling, attenuating M1 macrophage polarization and reducing IL‑6, IL‑1β, TNF‑α34.
• EGFR inhibition in microglia can attenuate NLRP3 inflammasome activity, thereby lowering SASP‑like cytokine release and improving vagal tone, both of which influence pain perception and mitochondrial function.

Experimental Design

Population: 120 participants aged 65‑80, stratified by baseline pain tolerance (low vs. high) and epigenetic age acceleration (>5 years). Intervention: Double‑blind, placebo‑controlled; 200 mg emodin standardized extract daily for 16 weeks. Outcomes (measured at baseline, week 8, week 16):

• Pain tolerance: cold‑pressor test duration and pressure‑pain threshold.
• Epigenetic age: Horvath and Hannum clocks from peripheral blood DNA methylation.
• Inflammatory biomarkers: plasma IL‑6, IL‑1β, TNF‑α, CRP.
• Neuroimmune markers: CSF sTREM2 and PET microglial activation (subset n=30).
• Vagal tone: HRV RMSSD during paced breathing.
• Mitochondrial function: peripheral blood mononuclear cell OCR/ECAR.

Expected Outcomes

If the hypothesis holds, emodin will:

1. Significantly increase pain tolerance (≈20 % improvement vs placebo).
2. Reduce epigenetic age acceleration by ≥3 years on both clocks.
3. Decrease pro‑inflammatory cytokines and microglial activation signals.
4. Show parallel improvements in vagal tone and mitochondrial respiration. Mediation analysis will test whether changes in inflammatory biomarkers mediate the effect of emodin on pain tolerance and epigenetic age.

Potential Pitfalls & Alternatives

• Insufficient CNS penetration: if CSF biomarkers unchanged, hypothesize peripheral immune modulation sufficient to influence pain via vagal afferents; repeat with higher dose or nanoparticle formulation.
• Off‑target effects: monitor liver enzymes and QT interval; include an EGFR‑inactive analog control to isolate EGFR dependence.
• Heterogeneity in baseline inflammation: pre‑screen for elevated CRP; perform subgroup analysis to see if effect is confined to high‑inflammation stratum.

Falsifiability

Failure to observe a statistically significant improvement in pain tolerance or a reduction in epigenetic age acceleration relative to placebo after 16 weeks will falsify the hypothesis. Similarly, if emodin alters pain tolerance without corresponding changes in inflammatory or neuroimmune markers, the proposed mechanistic link must be revised.